Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Lovaza® in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction documented by at least 2 of the following:~  1. Typical symptoms~ 2. Abnormal levels of cardiac biomarkers (troponin I or T or CK-MB mass) with at least one determination \> 99th percentile or ULN for the laboratory~ 3. ECG findings diagnostic of myocardial infarction based on the American College of Cardiology criteria.~* Status-post urgent or emergent PCI~* Have a Thrombolysis In Myocardial Infarction (TIMI) flow grade = 3 (complete perfusion) post PCI.~* Have the capacity for informed consent (e.g. without significant dementia or sedation from medication)~* Ingested 325 mg of chewed aspirin as part of the acute coronary syndrome treatment protocol.~Exclusion Criteria:~* No informed consent~* Daily aspirin use prior to index hospitalization~* Known prior myocardial infarction~* Known pregnancy~* Known allergy to fish, fish oil, or aspirin~* Known active internal or non-superficial bleeding, known bleeding disorder, coagulation defect, or thrombocytopenia~* Thrombolysis in the past 12 hours~* Treatment with a IIbIIIa inhibitor during index hospitalization~* Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg~* Severe uncontrolled hypertension (≥180/110) or hypertensive retinopathy~* A history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal (not hemorrhoidal) or genitourinary bleeding in the past 6 weeks~* A history of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit~* A known arteriovenous malformation or aneurysm~* Severe liver insufficiency (ALT ≥ 3 times normal)~* Renal insufficiency requiring dialysis~* A known diagnosis of vasculitis~* Participation in another clinical study~* History of malignancy, except subjects who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma~* Oral contraceptive use~* Daily use of NSAIDs~* History of drug or alcohol abuse, or current weekly alcohol consumption \>14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 shot of alcohol)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lovaza® (Type: EXPERIMENTAL): Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
- Corn Oil (Type: PLACEBO_COMPARATOR): The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).